Pancreatic Cancer From the Patient Perspective: The Time to Act is Now.
cancer
medical education
patient engagement
patient feedback
quality improvement
quality of life
Journal
Journal of patient experience
ISSN: 2374-3735
Titre abrégé: J Patient Exp
Pays: United States
ID NLM: 101688338
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Pancreatic cancer is a disease requiring urgent attention from governments and policymakers. Recently, a state of emergency has been declared for this cancer-being the fourth most common cause of cancer deaths in the European Union, it has the lowest survival rate of all common cancers. One of the major reasons pancreatic cancer is associated with such poor outcomes is because it is usually diagnosed at a late stage. Also, investment in research for effective targeted therapies is lacking. This is the perspective of a white paper developed by Digestive Cancers Europe, an umbrella organisation representing European patient organisations. It has been developed after consultation with pancreatic cancer patients, representatives of cancer patient organisations and leading pancreatic cancer healthcare professionals. The purpose of the paper is to highlight the key urgent unmet needs in pancreatic cancer from the patient perspective, ultimately with a view to improve patient care and outcomes in this very challenging disease.
Identifiants
pubmed: 35846247
doi: 10.1177/23743735221112633
pii: 10.1177_23743735221112633
pmc: PMC9277424
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23743735221112633Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Cancer Epidemiol. 2018 Aug;55:52-60
pubmed: 29777994
BMC Med. 2020 Dec 10;18(1):388
pubmed: 33298026
Radiat Oncol. 2019 Aug 8;14(1):141
pubmed: 31395068
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Surg. 2015 Sep;21 Suppl 1:S72-7
pubmed: 26123386
Expert Rev Mol Med. 2021 Dec 15;23:e21
pubmed: 34906271
Acta Oncol. 2016 Sep - Oct;55(9-10):1158-1160
pubmed: 27551890
United European Gastroenterol J. 2021 Sep;9(7):860-871
pubmed: 34431604
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):81
pubmed: 33444531
Mol Carcinog. 2012 Jan;51(1):64-74
pubmed: 22162232
Am J Cancer Res. 2017 Feb 01;7(2):357-369
pubmed: 28337383
Open Access Maced J Med Sci. 2019 Feb 14;7(4):663-671
pubmed: 30894932